Safety of valproate in porphyria cutanea tarda

R. D'Alessandro, E. Rocchi, E. Cristina, M. Cassanelli, G. Benassi, D. Pizzino, A. Baldrati, A. Baruzzi

Research output: Contribution to journalArticlepeer-review


Treatment of epileptic seizures in patients with hepatic porphyrias is a challenging problem due to enzymatic induction activity of phenobarbital (PB), phenytoin, (PHT), carbamazepine (CBZ), and clonazepam (CZP). We present the case of a patient with partial seizures treated with PHT and showing clinical signs and biochemical abnormalities of porphyria cutanea tarda (PCT). We withdrew PHT and treated the patient with sodium valproate (VPA). We followed the patient for 6 months during VPA therapy. During this period, clinical signs of PCT disappeared and biochemical values normalized. Our study shows that VPA is a safe treatment in epileptic patients with PCT.

Original languageEnglish
Pages (from-to)159-162
Number of pages4
Issue number2
Publication statusPublished - 1988

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)


Dive into the research topics of 'Safety of valproate in porphyria cutanea tarda'. Together they form a unique fingerprint.

Cite this